RecruitingPhase 3NCT07548164

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Alternative Boost Approaches in Radiation Therapy IRreversible Electroporation Versus RADIAtioN BoosT for Intermediate Risk Prostate Cancer (IRRADIANT)

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

224 participants

Start Date

Apr 16, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).

Eligibility

Sex: MALE

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called NanoKnife System and Stereotactic Body Radiation Therapy for people with prostate cancer. The study is currently recruiting participants at 8 locations. People eligible for this study include men.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENanoKnife System

The NanoKnife System is the device that is used for Irreversible Electroporation/IRE. The NanoKnife Generator is a microprocessor-controlled low energy direct current (LEDC) irreversible electroporation device.

RADIATIONStereotactic Body Radiation Therapy

Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.